BIOLOGICS USE in SLE in 23 CENTERS - DATA FROM the INTERNATIONAL REGISTRY for BIOLOGICS in SLE

Karolinska Univ Hosp, Stockholm, SwedenRigshosp, DK-2100 Copenhagen, DenmarkCedars Sinai UCLA, Los Angeles, CA USADalhousie Univ & Capital Hlth, Halifax, NS, CanadaJohns Hopkins Univ Hosp, Baltimore, MD 21287 USAUCL, London, EnglandMcGill UHC RI, Montreal, PQ, CanadaMcGill Univ, Ctr Hlth, Montreal, PQ, CanadaMcGill UHC RVH, Montreal, PQ, CanadaKarolinska Inst, Stockholm, SwedenHanyang Univ, Hosp Rheumat Dis, Seoul 133791, South KoreaHosp Clin Barcelona, Barcelona, SpainHosp Cruces, Bizkaia, SpainHosp Virgen Rocio, Seville, SpainHosp Miguel Servet, Zaragoza, SpainHosp San Cecilio, Granada, SpainHosp Son Dureta, Palma de Mallorca, SpainHosp Carlos Haya, Malaga, SpainIstanbul Univ, Istanbul Fac Med, Istanbul, TurkeyNorthwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USAUniv Manitoba, Winnipeg, MB, CanadaCareggi Hosp Florence, Florence, ItalyUniv Szeged, Szeged, HungaryUniv Padua, Padua, ItalyUniv Debrecen, H-4012 Debrecen, HungaryHlth Sci Ctr, Debrecen, HungaryUniv Cattolica Sacro Cuore, Div Rheumatol, I-00168 Rome, ItalyCatholic Univ, Rheumatol Unit, Rome, ItalyUniversidade Federal de São Paulo, Escola Paulista Med, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, São Paulo, BrazilWeb of Scienc

Management of Recurrent Thrombosis in Antiphospholipid Syndrome

One of the challenges of managing patients with antiphospholipid syndrome is the prevention of rethrombosis (secondary prophylaxis). Risk stratification, i.e. traditional cardiovascular and thrombosis risk factors, systemic autoimmune diseases, antiphospholipid antibody profile, and the intensity of anticoagulation are all relevant to the management of APS patients with recurrent thrombosis. The paper will review "state of the art" strategies for optimizing therapy for APS patients with recurrent thrombosis